Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graham, G. D.
Right arrow Articles by Turkel, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graham, G. D.
Right arrow Articles by Turkel, C. C.
Neurology 2000;55:1376-1379
© 2000 American Academy of Neurology
Brief Communications

MR spectroscopy study of dichloroacetate treatment after ischemic stroke

G. D. Graham, MD, PhD, P. B. Barker, DPhil, W. M. Brooks, PhD, D. C. Morris, MD, W. Ahmed, MD, E. Bryniarski, MD, D. O. Hearshen, MD, J. A. Sanders, PhD, B. A. Holshouser, PhD and C. C. Turkel, PharmD

From the University of New Mexico (Drs. Graham, Brooks, Ahmed, and Bryniarski) and the Albuquerque Veterans Administration Medical Center (Drs. Graham and Sanders), Albuquerque; Henry Ford Hospital (Drs. Barker, Morris, and Hearshen), Detroit, MI; Loma Linda University (Dr. Holshouser), CA; and Cypros Pharmaceutical Corporation (Dr. Turkel), Carlsbad, CA.

Address correspondence and reprint requests to Dr. Glenn D. Graham, Neurology/127, VA Medical Center, 1501 San Pedro Drive SE, Albuquerque, NM 87108; e-mail: graham{at}unm.edu

In a double-blind, placebo-controlled study, we used 1H MR spectroscopy to assess the effect of a single infusion of sodium dichloroacetate on lesion lactate 1 to 5 days after ischemic stroke. Apparent trends toward a reduction in lactate/N-acetyl compound ratios were seen at the higher drug doses employed, and in patients treated in the first 2 days following infarction. Use of spectroscopic measures as endpoints is feasible in acute stroke clinical trials.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by AAN Enterprises, Inc.